DetailsCategory: DNA RNA and CellsPublished on Monday, 27 July 2020 12:36Hits: 584
- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients
- Two RECIST unconfirmed partial responses and two patients with stable disease through six months
- Manageable toxicity profile, with only one patient exhibiting TC-210-related non-hematologic Grade >2 toxicity
- Translational data demonstrated T cell expansion and cytokine production
CAMBRIDGE, MA, USA I July 26, 2020 I TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors. All five patients showed tumor regression including two RECIST unconfirmed partial responses (one of which remains subject to independent central review) and two patients with stable disease through six months. Translational data further demonstrated TRuC-T cell expansion and activation. A manageable toxicity profile was observed with only one patient exhibiting TC-210-related non-hematologic grade >2 toxicity and no evidence of neurotoxicity or on-target, off-tumor toxicity.
We are delighted that our very first dose of TC-210 induced consistent tumor regression and clinical benefit in heavily pre-treated cancer patients, said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2Therapeutics. There are very few options for patients with solid tumors and those expressing mesothelin represent a significant frontier of unmet medical need. While these are early data requiring further study, we are encouraged by the potential of our TRuC-T cells as we continue to enroll and treat patients with the goal of quickly finding a recommended Phase 2 dose for TC-210.
Based on my prior experience working with both TCR-T and CAR-T cells, including the FDA approval of Kymriah, observing consistent clinical benefit in patients at presumably suboptimal T cell doses is quite meaningful, said Alfonso Quints-Cardama, M.D., Chief Medical Officer of TCR2Therapeutics. These early TC-210 data suggest our approach may overcome the challenges faced by many T cell therapies in the hostile solid tumor microenvironment. Our enrolled patients have failed multiple lines of therapy, including standard chemotherapy, checkpoint inhibitors and in some cases other mesothelin-directed approaches, in indications where survival has been historically shorter than six months.
The primary objectives of the Phase 1 portion of the study are to define the safety profile of TC-210 in patients whose tumors overexpress mesothelin and to determine the recommended Phase 2 dose (RP2D). Secondary objectives include overall response rate (ORR) and disease control rate (DCR). Exploratory objectives include the assessment of expansion, tumor infiltration, and persistence of TC-210 T cells.
Summary of trial conduct, baseline characteristics and TC-210 dose:
Key clinical findings from the first five patients treated with TRuC-T cells include:
About the Phase 1/2 Clinical Trial in Advanced Mesothelin-Expressing Solid Tumors
The Phase 1/2 clinical trial (NCT03907852) is evaluating the safety and efficacy of TC-210, TCR2s T-cell receptor fusion construct directed against mesothelin. The trial is enrolling patients with mesothelin expressing NSCLC, ovarian cancer, cholangiocarcinoma, and malignant pleural/peritoneal mesothelioma. The Phase 1 dose escalation portion of the clinical trial utilizes a modified 3+3 design withfour increasing TC-210 T cell doses. At each dose, TC-210 will be tested in two separate dose levels: first without lymphodepletion and then following lymphodepleting chemotherapy. The Phase 1 portion of the clinical trial is ongoing.
In the Phase 2 portion of the clinical trial, approximately 50 patients are planned to receiveTC-210at the RP2D in four distinct cohorts according to their cancer diagnosis: NSCLC, ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Each cohort will include ten patients, except the NSCLC cohort which will include 20patients with eight patients to receive TC-210as single agent and 12 patients to receive TC-210in combination with a programmed cell death 1(PD-1)blocking antibody.
About Mesothelin-Expressing Solid Tumors
Mesothelin is a cell-surface glycoprotein highly expressed in a wide range of solid tumors, including malignant pleural/peritoneal mesothelioma, ovarian cancer, cholangiocarcinoma, breast cancer, pancreatic cancer and others. Overexpression of mesothelin is associated with poorer prognosis in some cancers due to its active role in both malignant transformation and tumor aggressiveness by promoting cancer cell proliferation, invasion, and metastasis. Of the wide range of solid tumors expressing mesothelin, non-small cell lung cancer, ovarian cancer, mesothelioma and cholangiocarcinoma represent a significant patient population up to 80,000 in the United States alone.
TCR2 Therapeutics Conference Call and Webcast
TCR2 Therapeutics will host a conference call and webcast on Monday, July 27th at 8:00am E.T. The webcast and presentation will be made available on the TCR2 Therapeutics website in the Investors section under Events at http://investors.tcr2.com/events. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
About TCR2 Therapeutics
TCR2Therapeutics Inc.is a clinical-stage immunotherapy company developing a pipeline of novel Tcell therapies for patients suffering from solid tumors or hematological malignancies.TCR2sproprietary T cell receptor (TCR) Fusion Construct Tcells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent ofhuman leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Companys lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Companys lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visitwww.tcr2.com.
SOURCE: TCR2 Therapeutics
Continued here:
- Diagnosing Pleural Mesothelioma with Lung Fluid: The Battle of the Biomarkers - Surviving Mesothelioma - March 24th, 2017 [March 24th, 2017]
- Republican Health Care Bill Includes Asbestos Exposure Funding for Libby Residents - Mesothelioma.com - March 24th, 2017 [March 24th, 2017]
- Pembrolizumab shows promise in treatment of mesothelioma - Science Daily - March 24th, 2017 [March 24th, 2017]
- Veterans with Mesothelioma Benefit from Telephone Triage - Asbestos.com - March 24th, 2017 [March 24th, 2017]
- Mesothelioma Survival Rates Slowly Improving - Mesothelioma.net Blog (blog) - March 24th, 2017 [March 24th, 2017]
- Understanding Mesothelioma Caregiver Styles - Asbestos.com (blog) - March 24th, 2017 [March 24th, 2017]
- Mesothelioma Patients Turn to Cannabis - AlterNet - March 24th, 2017 [March 24th, 2017]
- Mesothelioma | Overview, Treatment Options and Survivor Stories - March 24th, 2017 [March 24th, 2017]
- Accelerated Approval Granted to Drug in Mesothelioma Research Pipeline - MesotheliomaHelp.org (blog) - April 8th, 2017 [April 8th, 2017]
- New Study Affirms Mesothelioma Survival Benefit with Post-Surgical IMRT, According to Surviving Mesothelioma - Benzinga - April 8th, 2017 [April 8th, 2017]
- The Key to Mesothelioma Treatment Success with Immunotherapy - Surviving Mesothelioma - April 8th, 2017 [April 8th, 2017]
- New Evidence Supports Post-Surgical IMRT for Mesothelioma Treatment - Surviving Mesothelioma - April 8th, 2017 [April 8th, 2017]
- Shorter Mesothelioma Survival Linked to High Platelet Count - Asbestos.com - April 8th, 2017 [April 8th, 2017]
- Mesothelioma Victims Center Now Appeals to All Diagnosed ... - Yahoo Finance - April 8th, 2017 [April 8th, 2017]
- Early research suggests first immunotherapy for mesothelioma on the horizon - Medical Xpress - June 6th, 2017 [June 6th, 2017]
- Bristol-Myers Squibb's Opdivo, Yervoy put the brakes on mesothelioma in phase 2 - FiercePharma - June 6th, 2017 [June 6th, 2017]
- Methanol from African Plants Kills Mesothelioma Cells - Asbestos.com - June 6th, 2017 [June 6th, 2017]
- Mesothelioma Patients to be Celebrated on National Cancer Survivor's Day - Mesothelioma.net Blog (blog) - June 6th, 2017 [June 6th, 2017]
- IO Strategy In Mesothelioma Finally Gets Mapped Out | Seeking Alpha - Seeking Alpha - June 6th, 2017 [June 6th, 2017]
- New Blood Test Could Mean Earlier Mesothelioma Diagnosis - Surviving Mesothelioma - June 6th, 2017 [June 6th, 2017]
- Using Viruses to Boost Mesothelioma Immunotherapy - Asbestos.com - June 6th, 2017 [June 6th, 2017]
- Resilience Can Help Mesothelioma Patients and Their Families ... - MesotheliomaHelp.org (blog) - June 7th, 2017 [June 7th, 2017]
- Janet Stanton Schnitzer Remembers Her Father's Mesothelioma Battle - Mesothelioma & Asbestos Awareness Center (blog) - June 7th, 2017 [June 7th, 2017]
- Treating Mesothelioma: A rare, aggressive caner - ABC2 News - June 7th, 2017 [June 7th, 2017]
- Asbestos and Mesothelioma Lawsuits: What to Expect | Nolo.com - June 7th, 2017 [June 7th, 2017]
- Mesothelioma Victims Center Now Urges a Roofer/Insulator With Mesothelioma to Call About Why It Is Necessary to ... - PR Newswire (press release) - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Patients May Have Another Treatment Option With FDA Expanded-Use Approval of Lung Cancer Drug - MesotheliomaHelp.org (blog) - June 9th, 2017 [June 9th, 2017]
- A Breath Test for Mesothelioma? - Surviving Mesothelioma - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Cancer: 12 Essential Facts - Asbestos News - June 9th, 2017 [June 9th, 2017]
- Mesothelioma - NHS Choices - June 9th, 2017 [June 9th, 2017]
- 15-year Mesothelioma Survivor Living Life By Design - Asbestos.com (blog) - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Cancer Overview | Experienced Lawyers Here to Help - June 11th, 2017 [June 11th, 2017]
- Mesothelioma Victims Center Now Urges a Diagnosed Machinist to Call for Direct Access to Journeyman-Level ... - PR Newswire (press release) - June 12th, 2017 [June 12th, 2017]
- Honeywell Fails in Appeal Against Mesothelioma Verdict - Mesothelioma.net Blog (blog) - June 12th, 2017 [June 12th, 2017]
- Mesothelioma Patients Can See Improved Survival By Reporting Side Effects - MesotheliomaHelp.org (blog) - June 12th, 2017 [June 12th, 2017]
- What is Mesothelioma? | Surviving Mesothelioma - Surviving Mesothelioma - June 13th, 2017 [June 13th, 2017]
- Cases of Pleural Mesothelioma - Surviving Mesothelioma - June 13th, 2017 [June 13th, 2017]
- The Importance of Cancer Research in Immunotherapy - Mesothelioma.com (blog) - June 14th, 2017 [June 14th, 2017]
- Hopes High for Mesothelioma Immunotherapy Treatment ... - Mesothelioma.net Blog (blog) - June 14th, 2017 [June 14th, 2017]
- Asbestos Sprayers Face Higher Lifetime Mesothelioma Risk ... - Surviving Mesothelioma - June 14th, 2017 [June 14th, 2017]
- Remembering Loved Ones Lost to Mesothelioma, Looking Forward to Progress in Treatment - MesotheliomaHelp.org (blog) - June 14th, 2017 [June 14th, 2017]
- Chicago Public Schools Ignoring Asbestos Problem - Mesothelioma.com - June 16th, 2017 [June 16th, 2017]
- Length of Time Between Surgeries a Marker for Mesothelioma Survival - Surviving Mesothelioma - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Survivor Deals with Pain 15 Years After Surgery - Asbestos.com (blog) - June 16th, 2017 [June 16th, 2017]
- Nivolumab and Ipillimumab Show Promise in Treating Mesothelioma Recurrence - Mesothelioma.com - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Patients Should Heed FDA Warnings Regarding Miracle Cures - MesotheliomaHelp.org (blog) - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Patients May Benefit from Marijuana Research - Mesothelioma.net Blog (blog) - June 17th, 2017 [June 17th, 2017]
- The Challenges of Research in Immunotherapy - Mesothelioma.com (blog) - June 17th, 2017 [June 17th, 2017]
- Despite Mesothelioma Diagnosis, Dad Loved Father's Day - Asbestos.com (blog) - June 17th, 2017 [June 17th, 2017]
- I Want to Keep Writing About Mesothelioma and My Family's Journey Because It Matters - MesotheliomaHelp.org (blog) - June 17th, 2017 [June 17th, 2017]
- Mesothelioma Clinical Trial Opens with High Expectations - Asbestos.com - June 17th, 2017 [June 17th, 2017]
- Cediranib May be Safe Supplement to Mesothelioma Treatment - Surviving Mesothelioma - June 17th, 2017 [June 17th, 2017]
- New Trial Finds VEGF-Inhibitor May Safely Boost Mesothelioma ... - Benzinga - June 18th, 2017 [June 18th, 2017]
- Mesothelioma Symptoms - Identify Early Warning Signs - June 18th, 2017 [June 18th, 2017]
- Mesothelioma Victims Center Now Urges a Diagnosed Construction Worker or Plumber to Call for Instant Access to the ... - PR Newswire (press release) - June 20th, 2017 [June 20th, 2017]
- Mesothelioma Treatment May Benefit From New Discovery ... - Mesothelioma.net Blog (blog) - June 20th, 2017 [June 20th, 2017]
- The Influence of BAP1 on Mesothelioma Survival - Surviving Mesothelioma - June 20th, 2017 [June 20th, 2017]
- Clinical Trial to Assess If Radiation Therapy Can Bring Effective Relief from Mesothelioma Pain - MesotheliomaHelp.org (blog) - June 20th, 2017 [June 20th, 2017]
- Asbestos Exposure Attorneys - Mesothelioma Lawsuits ... - June 20th, 2017 [June 20th, 2017]
- Can a Breath Test Diagnose Mesothelioma in the Early Stages? - Asbestos.com - June 21st, 2017 [June 21st, 2017]
- Mesothelioma Compensation Center Now Urges an Electric Utility Worker or Electrician with Mesothelioma to Aim High ... - PR Newswire (press release) - June 21st, 2017 [June 21st, 2017]
- Nurse Explains Mesothelioma Staging - MesotheliomaHelp.org (blog) - June 21st, 2017 [June 21st, 2017]
- 5 Questions: Treatment options exist for mesothelioma - Las Vegas Review-Journal - June 21st, 2017 [June 21st, 2017]
- Steve McQueen's Wife Pushes for Asbestos Ban - Mesothelioma.com - June 21st, 2017 [June 21st, 2017]
- Remembering Mesothelioma Victims in the UK - Mesothelioma.com (blog) - June 21st, 2017 [June 21st, 2017]
- Peritoneal Cancer Index: What it Means for Mesothelioma Patients - Mesothelioma & Asbestos Awareness Center (blog) - June 21st, 2017 [June 21st, 2017]
- Mesothelioma Risk Continues to Rise for Decades After Asbestos Exposure - Surviving Mesothelioma - June 21st, 2017 [June 21st, 2017]
- Nintedanib Combination Delayed Progression in Malignant Mesothelioma - Cancer Network - June 22nd, 2017 [June 22nd, 2017]
- Polish Study Confirms That Mesothelioma Risk Only Increases With ... - Mesothelioma.net Blog (blog) - June 22nd, 2017 [June 22nd, 2017]
- The Mesothelioma Victims Center Now Urges a Diagnosed Navy ... - PR Newswire (press release) - June 22nd, 2017 [June 22nd, 2017]
- Targeted Therapy May Soon be Primary Approach for Mesothelioma Treatment - MesotheliomaHelp.org (blog) - June 23rd, 2017 [June 23rd, 2017]
- Time Between Surgeries Helps Predict Mesothelioma Survival - Asbestos.com - June 23rd, 2017 [June 23rd, 2017]
- Testicular and Cardiac Mesothelioma - Surviving Mesothelioma - June 23rd, 2017 [June 23rd, 2017]
- Mesothelioma Veterans Center - Access Benefits & VA Claims - June 23rd, 2017 [June 23rd, 2017]
- Malignant Mesothelioma (Asbestos Cancer) > The Mesothelioma ... - June 23rd, 2017 [June 23rd, 2017]
- Mesothelioma Law Firm | Sokolove Law - June 23rd, 2017 [June 23rd, 2017]
- MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma - Surviving Mesothelioma - June 24th, 2017 [June 24th, 2017]
- Mesothelioma Survival Rate | Factors Affecting Survivorship - June 24th, 2017 [June 24th, 2017]
- Scientists "Turn Off" Tumor-Protecting Protein in New Mesothelioma Study, According to Surviving Mesothelioma - Benzinga - June 26th, 2017 [June 26th, 2017]
- Symptoms of Mesothelioma - Critical Signs to Watch For - June 26th, 2017 [June 26th, 2017]